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Recent insights into the neural circuits controlling energy balance and glucose homeostasis
have rekindled the hope for development of novel treatments for obesity and diabetes. However,
many therapies contribute relatively modest beneficial gains with accompanying side effects,
and the mechanisms of action for other interventions remain undefined. This Review summarizes
current knowledge linking the neural circuits regulating energy and glucose balance with current
and potential pharmacotherapeutic and surgical interventions for the treatment of obesity and
diabetes.Introduction
Obesity, diabetes, and associated disorders represent a major
public health challenge for North America, Europe, and increas-
ingly the rest of the world. Both obesity and diabetes inflict
health and economic burdens that require coordinated strate-
gies to both prevent and treat these disorders. Indeed, a major
barrier in the management and prevention of obesity is that
weight loss due to lifestyle changes alone is inherently difficult.
For many, this means that dieting-induced weight loss initially
results in tangible beneficial effects but is often followed by a
return to previous energy intake and consequently a rebound
weight gain.
Numerous neurobiological and physiological mechanisms
that regulate energy balance exist. In particular, it has become
increasingly evident that the brain plays an important role in
sensing energy demands and storage in order to maintain/
defend body weight within a rather tight range. Studies ranging
from worms, flies, and mice to humans have identified key
conserved genes and neural pathways that are critical in regu-
lating energy balance and glucose homeostasis. Moreover, the
identification of human mutations in these or analogous path-
ways has led to hope that it may be possible to develop rational
strategies based on animal model studies that may ultimately
lead to successful therapeutic intervention in humans. In this
Review, we will highlight how advances in understanding the
neurophysiology underlying metabolism, including an increased
understanding of neural circuits, may hold promise for develop-
ment of adjunct therapies in the treatment of obesity and associ-
ated co-morbidities, including diabetes. Several recent Reviews
have provided more detailed information and review of the pri-
mary literature regarding the respective circuits and approaches
highlighted here (Barsh et al., 2000; Cone, 2005; Deisseroth,
2012; Farooqi and O’Rahilly, 2005; Heisler et al., 2003; Myers
and Olson, 2012; Powley et al., 2005; Schwartz and Porte,
2005; Wikberg and Mutulis, 2008).A Brief Overview of Neural Circuits Regulating Feeding
and Energy and Glucose Homeostasis
The central melanocortin system is comprised of neurons in
the hypothalamic arcuate nucleus and brainstem that pro-
duce pro-opiomelanocortin (Pomc), the precursor polypeptide
of the biologically active melanocortin receptor peptide agonist,
a-melanocyte-stimulating hormone (a-MSH). Additional pep-
tides within the arcuate nucleus that contribute to the melano-
cortin system include Agouti gene-related peptide (AgRP), an
endogenous inverse agonist of the melanocortin 4 receptor
(Mc4r), and Neuropeptide Y (NPY), which is co-expressed with
AgRP. Elucidating the physiological importance of this system
in regulating energy balance and glucose homeostasis brought
the hypothalamic arcuate nucleus to the forefront of research
aimed at understanding the neural control of energy balance
(Cone, 2005; Schwartz and Porte, 2005).
Pomc and NPY/AgRP neurons are prototypical players in
the regulation of energy intake and expenditure for several rea-
sons. In particular, exogenous administration of a-MSH potently
inhibits food intake via activation of central melanocortin re-
ceptor-expressing neurons (Cone, 2005; Rossi et al., 1998;
Schwartz and Porte, 2005). Conversely, administration of
NPY effectively stimulates food intake via action at NPY-Y re-
ceptors in the brain (Clark et al., 1984; Yulyaningsih et al.,
2011). Several studies have used opto- and chemogenetic tech-
niques to attempt tomanipulate the activity of varying genetically
targeted populations of neurons with a role in feeding behavior
and metabolism, including but not limited to AgRP neurons
(Aponte et al., 2011; Atasoy et al., 2012; Krashes et al., 2011;
Krashes et al., 2013) and Pomc neurons (Aponte et al., 2010;
Zhan et al., 2013). Stimulation of arcuate Pomc neurons resulted
in a reduction in food intake, whereas activation of arcuate AgRP
neurons resulted in increased food intake and food-seeking
behaviors (Aponte et al., 2010; Krashes et al., 2011; Zhan
et al., 2013). The Pomc-induced reduction in food intake wasCell 161, March 26, 2015 ª2015 Elsevier Inc. 133
Figure 1. Integrated Model of the Central
Melanocortin System and Connected Re-
gions within the Nervous System Involved
in Obesity and Diabetes
Recent discoveries highlight a circuitry within the
brain that includes the hypothalamus as well as
midbrain/hindbrain areas in the regulation of
energy expenditure. This circuitry has also been
demonstrated to have an overlapping role in the
management of glucose homeostasis. Impor-
tantly, several neurotransmitters and peptides
contribute to a distributed network of receptor
systems within this circuit and provide potential
substrates for non-surgical therapeutic interven-
tion. Similarly, advancing technologies have
raised potential surgical and non-surgical manip-
ulation of cellular and nerve activity as a viable
strategy in this circuit to combat obesity and
diabetes. Abbreviations: NPY = neuropeptide Y;
Pomc = pro-opiomelanocortin; AgRP = Agouti
gene-related peptide; Arc = arcuate nucleus;
GLP-1 = glucagon-like peptide 1.dependent upon melanocortin receptors within the paraventric-
ular hypothalamus (PVH), a hypothalamic nucleus that is a direct
target of arcuate melanocortin neurons. Stimulation of arcuate
AgRP neurons elicited feeding behavior via projections to the
thalamus, the hypothalamus, and the basal forebrain (Atasoy
et al., 2012). Interestingly, either the neurotransmitter GABA or
NPY is required for the rapid stimulation of feeding, whereas
the neuropeptide AgRP, through action onMc4 receptors, is suf-
ficient to induce feeding over a delayed yet prolonged period
(Krashes et al., 2013). GABA from NPY/AgRP neurons of the hy-
pothalamic arcuate nucleus may also play an important role in
the regulation of feeding behaviors via direct actions within the
hindbrain (Wu et al., 2009). Moreover, neurons of the nucleus
of the solitary tract in the caudal medulla might counterbalance
this activity (Wu et al., 2012). Neurons of the PVH also recipro-
cally innervate arcuate NPY/AgRP neurons, providing a regula-
tory loop in the control of feeding behavior (Krashes et al.,
2014). Collectively, these data suggest that in addition to a
core circuit, AgRP neuron projections and reciprocal innerva-
tions may reveal key modulatory circuit nodes that are gated
or otherwise regulated by AgRP neuron projections (Atasoy
et al., 2012). Importantly, it’s currently unclear which circuits
are acutely involved in other complex metabolic processes
such as energy expenditure and glucose metabolism. Undoubt-
edly, similar parallel and redundant mechanisms involved in
regulating feeding behavior will be intertwined with various as-
pects of metabolism.
Both NPY/AgRP and Pomc neurons are also sensitive tometa-
bolic status (Cone, 2005; Yulyaningsih et al., 2011). In particular,
NPY/AgRP neurons are activated during fasting, whereas Pomc
neurons are activated following feeding and inhibited during fast-
ing. NPY/AgRP and Pomc neurons are also well positioned to
sense and integrate numerous nutrient and humoral signals
(Schwartz and Porte, 2005). Indeed, many of these signals in
the periphery and/or the central nervous system (CNS) have
been attributed to regulating feeding behavior and energy expen-134 Cell 161, March 26, 2015 ª2015 Elsevier Inc.diture via activity at these neurons (Figure 1). For example,
increased serum levels of the adipocyte-derived anorexigenic
peptide leptin activate Pomc neurons and stimulate the produc-
tion as well as the release of a-MSH (Cone, 2005; Schwartz et al.,
1997). Leptin inhibits NPY/AgRP neurons concomitantly sup-
pressing the production and release of NPY and AgRP. These
data and others support a primary role of arcuate Pomc and
NPY/AgRP neurons as first-order neurons in the neural control
of energybalance.However, itmust benoted that leptin-sensitive
neuronsdistributed across thebrainmaycontribute to the control
of feeding. For instance, loss of leptin receptors in either arcuate
Pomcneurons or adjacent neurons of the ventromedial hypothal-
amus (VMH) results in modest increases in adiposity largely
dependent upondeficits in energyexpenditure (Myers andOlson,
2012). Moreover, deletion of leptin receptors in both Pomc and
VMH neurons resulted in an additive effect on body weight.
Among other examples, leptin receptors on GABAergic neurons
of the lateral hypothalamic area (LHA) modulate the mesolimbic
dopaminergic system and decrease feeding (Leinninger et al.,
2009). Also, deficiency of leptin receptors in a brainstem site
called the dorsal vagal complex causes hyperphagia, resulting
in modest weight gain (Scott et al., 2011; Skibicka and Grill,
2009). Collectively, these data support a model of a distributed
network of melanocortin- and leptin-responsive neurons con-
tributing to the central regulation of energy homeostasis. Not sur-
prisingly, numerous nutrient and humoral receptors are also
widely distributedwithin theCNS, and researchers are identifying
multiple divergent and redundant roles for these receptors in the
regulation of metabolism.
The aforementioned evidence supports a well-defined action
of the central melanocortin system in regulating food intake
and body weight. However, it is less appreciated that the central
melanocortin system plays an important role in regulating
glucose metabolism, including insulin release and action (Far-
ooqi and O’Rahilly, 2005; Schwartz and Porte, 2005). In fact,
deficits in melanocortin signaling result in hyperinsulinemia,
fasting hyperglycemia, and frank diabetes (Berglund et al., 2014;
Cone, 2005; Myers and Olson, 2012). However, restoring Mc4r
expression selectively in the PVH reduces hyperphagia and
largely restores deficits in body weight independent of improved
glucose or insulin intolerance (Myers and Olson, 2012). In paral-
lel, loss of Mc4rs in parasympathetic and sympathetic nuclei of
the brainstem and spinal cord results in glucose and insulin intol-
erance largely independent of changes in food intake or body-
weight gain (Berglund et al., 2014; Myers and Olson, 2012).
Thus, the wide distribution of melanocortin receptors concomi-
tant with projection patterns of Pomc and NPY/AgRP neurons
contributes to their divergent effects on energy and glucose
homeostasis.
Several mutations inMc4r have been identified andmay repre-
sent the most common form of monogenic obesity in humans
(Barsh et al., 2000; Farooqi and O’Rahilly, 2005). Importantly,
the melanocortin system is remarkably conserved across spe-
cies from zebrafish and rodents to humans (Farooqi and O’Ra-
hilly, 2005; Sebag et al., 2013). Thus, neural circuits regulating
metabolic homeostasis in the mammalian hypothalamus have
an ancient origin, dating back to teleost fish. This long evolution
may explain the complexity as well as some of the main anatom-
ical and functional principles of these circuits governing energy
homeostasis in the mammalian hypothalamus.
In Search of Effective Appetite Suppressants
Although dieting and balanced nutrition are key to the manage-
ment of most, if not all, metabolic disorders, most dieters strug-
gle to maintain a rigid dietary regimen. Why is dieting so difficult?
There is certainly no single straightforward answer to this ques-
tion; however, brain-imaging studies in humans have offered
clues to neural correlates of obesity and responses to dieting.
In particular, dieting in humans changes the activity of intercon-
nected brain regions involved in the neural representations of
hunger and satiety and the anticipation of reward (Rosenbaum
et al., 2008). Neural activity induced by food cues also differs be-
tween obese and lean individuals in the prefrontal cortex (Zheng
andBerthoud, 2008). Paradoxically, these regions are involved in
the motivation to eat and are normally stimulated by dieting and
starvation. Typically, the brains of obese individuals appear to
react to food cues as if these individuals were in a state of nega-
tive energy balance (instead of energy repletion). Put another
way, defective brain processing in response to food cues in
obesity may result in inadequate reward and/or motivational pro-
cesses and, ultimately, hyperphagia.
Driven by various biological and environmental factors, hyper-
phagia is largely responsible for the current epidemic of obesity
and type 2 diabetes (T2DM). Thus, any successful weight-loss
strategy must address the issue of appetite. Accordingly, many
drugs approved by the US Food and Drug Administration
(FDA) for the treatment of obesity directly act on the nervous sys-
tem to suppress appetite (Table 1 and Figure 2) (Vetter et al.,
2010). The only peripherally acting drug currently approved to
treat obesity is Orlistat (trade name: Xenical or Alli), an inhibitor
of lipase activity that prevents fatty-acid absorption from the
diet (Bray, 2014). However, this drug commonly promotes loose
stools and, due to its lack of effect on the brain, minimally re-
duces appetite. As the field continues to build an understandingof neural circuitry regulating appetite, it has become evident that
a very large number of neural pathways and molecules are impli-
cated in modulating appetite levels. Consequently, the neural
circuits involved in metabolism offer numerous avenues for ther-
apeutic intervention in the treatment of hyperphagia (Figure 2).
Belowwe include a brief discussion on current appetite suppres-
sants and promising pharmacotherapeutics, with a special
emphasis on their potential mechanisms of action (Table 1 and
Figure 2). Information on the clinical features andmedical recom-
mendations for the drugs presented below can be found else-
where (Bray, 2014).
Overview of Current Anti-Obesity Drugs
Serotoninergic neurons play critical roles in the suppression of
feeding (Heisler et al., 2003). Accordingly, treatments that sup-
press central serotoninergic signaling result in hyperphagia
and weight gain in humans and rodents. Lorcaserin (trade
name: Belviq), an agonist of the serotonin receptor 5-HT2CR, re-
duces body weight largely dependent upon lowered food intake
in both humans and rodents (Martin et al., 2011; Smith et al.,
2010; Thomsen et al., 2008). Although 5-HT2CRs are widely ex-
pressed across the neuraxis (Julius et al., 1988), accumulating
evidence in rodents indicates that 5-HT2CR reduces appetite
and body weight by acting on Pomc neurons (Xu et al., 2008,
2010b). Notably, Lorcaserin is currently the only FDA-approved
drug monotherapy for obesity that specifically targets the brain.
However, clinical trials indicate that Lorcaserin yields weight los-
ses of 5%–10% of initial body weight after 1 year (Smith et al.,
2010) and is not marketed in Europe.
The naturally occurring peptide glucagon-like peptide 1
(GLP-1) inducesmultiple desirable anti-diabetic and anti-obesity
actions, and protease-resistant long-acting GLP-1 analogs are
currently available for the treatment of T2DM (Drucker, 2006).
Initial interest in the beneficial effects of GLP-1 on body weight
stemmed from the observation that GLP-1 inhibits food intake
(Turton et al., 1996). Both Exenatide (trade name: Byetta or
Bydureon—a synthetically derived exendin-4) and Liraglutide
(trade name: Victoza—a fatty acid-modified GLP-1) are long-
acting GLP-1 analogs that effectively lower blood glucose in dia-
betic patients and are approved by the FDA (see Table 1) to treat
T2DM (Juhl et al., 2002; Madsbad et al., 2004). Recent evidence
further suggests that both Exenatide and Liraglutide cross the
blood-brain barrier (Drucker, 2006; Hunter and Ho¨lscher, 2012)
and specifically act at the level of the hypothalamus to reduce
appetite (Drucker, 2006; Secher et al., 2014; Sisley et al.,
2014). Importantly, the FDA recently approved Liraglutide for
the treatment of chronic weight management. In particular, Lira-
glutide results in sustained weigh loss of 5%–10% of initial body
weight in obese patients (Astrup et al., 2009), which can be
attributed to both reduced appetite (concomitant with inhibition
of gastric emptying) and elevated energy expenditure in T2DM
individuals (Horowitz et al., 2012). While Liraglutide is a well-
tolerated drug, its long-term side effects are not well known,
and some concern has been raised due to a possible risk of
pancreatic cancer associated with GLP-1 agonist treatment (Co-
hen, 2013). Moreover, GLP-1 receptor agonists increase heart
rate and blood pressure in rats by stimulating the sympathetic
outflow to the cardiovascular system (Yamamoto et al., 2002).Cell 161, March 26, 2015 ª2015 Elsevier Inc. 135
Table 1. Select List of Current and Potential Future Therapeutics for the Treatment of Obesity and Diabetes
Pharmacology
Drug/Compound Trade/Brand Name
Receptors/Molecular
Pathways FDA Approval Applications(s)
Brain Area and/or Tissues
Involved
Lorcaserin Belviq 5ht2cr agonist yes—2012 obesity hypothalamus, cortex,
midbrain, and brainstem
Liraglutide Victoza GLP-1r agonist yes—2012 obesity and
diabetes
hypothalamus
Topiramate/
Phentermine
Qysemia inhibit several ionic
conductances as well as
carbonic anhydrase
isozymes/stimulate the
release of serotonin-
norepinephrine-dopamine
yes—2012 obesity hypothalamus and brainstem
Buproprion/
Naltrexone
Contrave dopamine and
norepinephrine reuptake
inhibitor/opioid receptor
antagonist
yes—2014 obesity hypothalamus
D-fenfluramine Pondimin, Ponderax, Adifax 5ht2cr agonist withdrawn obesity hypothalamus and brainstem
Orlistat Xenical and Alli inhibit gastric and pancreatic
lipases
yes—1999 obesity gut
Sibutramine Meridia serotonin-norepinephrine-
dopamine reuptake inhibitor
withdrawn obesity hypothalamus and brainstem
Ribonamant Zimulti CB1R antagonist withdrawn obesity hypothalamus and brainstem
Mc4R agonists N/A Mc4R no obesity hypothalamus and brainstem
Exenatide Byetta, Bydureon GLP-1r agonist yes —2005 T2DM hypothalamus
Metformin Glucophage, Glumetza,
Glucophage XR, Fortamet
suppress gluconeogenesis
pathways
yes—1995 T2DM liver
Pramlintide Symlin amylin receptor agonist yes—2005 T2DM hypothalamus and brainstem
Leptin Metreleptin LepRB agonist nob type 1 and 2
diabetes
hypothalamus
Device-Assisted
Device
Receptors/Molecular
Pathways FDA Approval Application(s)
Brain Area and/or Tissues
Involved
hfDBS neuronal excitability noa obesity hypothalamus
tDCs neuronal excitability noa obesity cortex
VNS neuronal excitability noa obesity cervical vagus nerve
VBLOC neuronal excitability yes—2015 obesity gastric vagus nerve
Lap-band—laparoscopic
adjustable gastric band
unknown yes—2001 obesity gut-brain communication
Roux-en-Y gastric bypass unknown N/A obesity and T2DM gut-brain communication
Vertical sleeve gastrectomy unknown N/A obesity and T2DM gut-brain communication
aApproved for indications not related to metabolic outcomes.
bApproved for the metabolic disorders of lipodystrophies.Current monotherapeutic approaches in the treatment of
obesity and diabetes have not been optimally effective. Emer-
ging strategies include combination drug therapy targeting mul-
tiple signaling mechanisms. Combination therapies have been
more efficacious than the aforementioned monotherapies, pre-
sumably due to the additive and synergic effects previously
observed by the drugs separately. There are two combination
drug therapies currently marketed in the treatment of obesity,
Phentermine/Topiramate (trade name: Qysemia) and Bupro-
pion/Naltrexone (trade name: Contrave). All four compounds136 Cell 161, March 26, 2015 ª2015 Elsevier Inc.have been previously approved on an individual basis by the
FDA in the treatment of various neurological disorders. Phenter-
mine and Bupropion are well-known stimulators of serotonin
and norepinephrine release from nerve endings. The enhanced
release of norepinephrine in sympathetically innervated tissues
is likely to increase metabolism (Nedergaard and Cannon,
2014). Moreover, at high doses, these two drugs effectively
reduce food intake and body weight in laboratory rodents
(Roth et al., 2008; Wright and Rodgers, 2013). Topiramate is an
anti-convulsant anecdotally reported to induce weight loss
Figure 2. Selected Therapeutic Options for
Treating Obesity and Diabetes by Targeting
the Brain
Current and promising therapeutics in the treat-
ment of both obesity and diabetes have targeted
neural connections including the melanocortin
system, via pharmacological and/or device-as-
sisted methods. Here we summarize a select
number of targets (i.e., receptors and brain re-
gions) that have been demonstrated to regulate at
least in part effects of energy balance and glucose
homeostasis.
Abbreviations: hfDBS= high-frequency deep brain
stimulation; VBLOC = vagal blocking; VNS = vagal
nerve stimulation; Mc4r =melanocortin 4 receptor;
DVC = dorsal vagal complex; PBN = parabrachial
nucleus; tDCS = transcranial direct current stim-
ulation; Arc = arcuate nucleus; VMH = ventrome-
dial hypothalamic nucleus; LHA = lateral hypo-
thalamic area; DMH = dorsal medial hypothalamic
nucleus; PVH = paraventricular hypothalamus;
DVC = dorsal vagal complex; IML = intermedio-
lateral cell column; BAT = brown adipose tissue;
WAT = white adipose tissue; DR = dorsal raphe
nucleus.(Astrup et al., 2004). Naltrexone is an antagonist of opioid re-
ceptors with little effect on food intake when administered
alone (Greenway et al., 2009). Although Naltrexone may act by
increasing the firing rates of Pomc neurons (Greenway et al.,
2009), the exact mechanisms of action of Naltrexone and Topir-
amate on energy balance are unclear. Importantly, the FDA has
recently approved the drug combinations Contrave and Qyse-
mia as an adjunct for chronic weight management (Table 1)
with both medications promoting weight losses of 8% to 10%
of initial body weight (Allison et al., 2012; Garvey et al., 2012;
Greenway et al., 2009). Interestingly, another combination medi-
cation called Empatic (trade name) that contains both Bupropion
and Zonisamide (another anti-convulsant) is currently under
phase 2 clinical trial (Jackson et al., 2014). Thus, with the recent
FDA approval and/or promising clinical trial results, combination
therapies show promise for therapeutic efficacy in the treatment
of obesity.
Novel Paradigms in Anti-Obesity Pharmacotherapy
Although many compounds acting on neural pathways con-
trolling appetite, glucose metabolism, and energy expenditure
were found to induce marked body-weight loss in animal models
and human clinical trials, leading to FDA approval, many of theseCell 16pharmacotherapies were subsequently
abandoned due to serious safety con-
cerns (Bray, 2009) (Table 1). This was
the case for D-fenfluramine (D-fen; trade
name: Pondimin, Ponderax, or Adifax), a
pharmacological agent that increases se-
rotonin content by stimulating synaptic
release of serotonin and blocking its re-
uptake into presynaptic terminals (Con-
nolly et al., 1997). Although D-fen showed
potent anorexigenic activity in humans
(McGuirk et al., 1991), it was removedfrom the market in 1997 due to its link to the development of car-
diovascular complications (Connolly et al., 1997). Other centrally
acting drugs have succumbed to a similar fate, including Rimo-
nabant (trade name: Zimulti), an antagonist of the type I cannabi-
noid receptor Cb1R. Rimonabant’s anti-obesity actions have
been attributed to altered excitability of Cb1Rs located in key hy-
pothalamic, striatal, and brainstem neurons (Cota et al., 2006).
Although Rimonabant was highly effective in reducing food
intake and body weight, its development was halted in 2009
due to its serious gastrointestinal and adverse psychiatric ef-
fects. Although combinatorial approaches have already raised
hope for safer ways of treating obese patients, even currently
FDA-approved drugs are not without safety concerns. Another
caveat of currently available drugs is their modest efficacy
when compared to bariatric surgery (Colquitt et al., 2014). The is-
sues discussed above have stimulated research aimed at iden-
tifying new classes of centrally acting appetite suppressants,
some of which are presented below.
Mc4 receptors have been considered prime targets in the
search for effective therapeutics managing obesity (Van der
Ploeg et al., 2006; Wikberg and Mutulis, 2008). In fact, several
Mc4 receptor agonists were reported to produce significant
reduction in adiposity in humans and monkeys (Fehm et al.,1, March 26, 2015 ª2015 Elsevier Inc. 137
2001; Kievit et al., 2013; Wellho¨ner et al., 2012). However, Mc4
receptor agonists have not progressed to the clinic due to poten-
tial side effects, in particular those affecting the autonomic ner-
vous system. For example, Mc4 receptor agonists such as
melanotan II may result in hypertension and priapism (Greenfield
et al., 2009; Van der Ploeg et al., 2002). These undesirable effects
are likely caused by the stimulation of preganglionic autonomic
neurons expressing Mc4 receptors (Sohn et al., 2013). However,
all Mc4 receptor agonists may not similarly alter autonomic func-
tion. A small peptide, RM-493, has been demonstrated to effec-
tively induce weight loss in non-human primates and humans
with no major impact on cardiovascular function (Kievit et al.,
2013). This agent is currently in clinical trials for genetic obesity.
Interestingly, Mc4 receptors may also be modulated by the mel-
anocortin receptor accessory proteins (Mrap1 and Mrap2) (Asai
et al., 2013; Sebag et al., 2013). TheseMrapsmay provide a sub-
strate to differentially target the beneficial effects of Mc4 recep-
tor activity on energy expenditure, glucose utilization, and other
metabolic parameters while minimizing the adverse side effects.
Recent work has also highlighted a potential role for the melano-
cortin system to regulate brown adipose tissue thermogenesis
as well as the browning/beiging of white adipose tissues (Ber-
glund et al., 2014; Dodd et al., 2015; Nedergaard and Cannon,
2014; Ruan et al., 2014; Williams et al., 2014). It’s currently un-
clear what contribution this thermogenesis may play in the regu-
lation of body composition and glucose homeostasis; however,
these data may aid in the development of Mc4 receptor agonists
to combat obesity and diabetes.
Recent efforts have also focused on exploring new ways of
potentiating the efficacy of currently available appetite suppres-
sants, including, most notably, leptin. Shortly after its discovery
(Zhang et al., 1994), leptin was shown to completely reverse the
hyperphagic and obese phenotype of leptin-deficient animals
and humans (Farooqi and O’Rahilly, 2005; Licinio et al., 2004;
Pelleymounter et al., 1995). Unfortunately, obesity is character-
ized by hyperleptinemia (Considine and Caro, 1996), rather
than leptin deficiency. Thus, to the vast majority of morbidly
obese individuals, leptin monotherapy is ineffective in lowering
food intake or body weight. However, since the normal fall of lep-
tin that accompanies weight loss is detected by the brain as a
starvation signal (Ahima and Flier, 2000), it has been proposed
that leptin administration during the course of dieting may
amplify weight loss and reinforce compliance (Rosenbaum
et al., 2008).
Several gut peptides have been demonstrated to potently
enhance or restore leptin sensitivity in diet-induced obesity.
Most notably, amylin, a pancreatic-derived small peptide, has
been shown to successfully enhance the effects of leptin admin-
istration on energy balance in obese rodents as well as in hu-
mans (Ravussin et al., 2009; Trevaskis et al., 2008). In addition,
recent advances in the synthesis of peptides with co-agonistic
properties have permitted the development of a new generation
of anti-obesity molecules. This includes a GLP-1::glucagon
unimolecular co-agonist (Day et al., 2009). This molecule was
shown to effectively reduce body weight in obese animals to
almost 30% of initial body weight in only 1 month. Leptin-
induced body-weight loss has also been shown to be consider-
ably potentiated by the GLP-1::glucagon co-agonist (Clemmen-138 Cell 161, March 26, 2015 ª2015 Elsevier Inc.sen et al., 2014). The chronic co-administration of leptin and
GLP-1::glucagon yielded an impressive 50% weight loss in
obese mice over 1 month and normalized glucose intolerance.
Another promising co-agonistic (dual peptide) strategy con-
sists of delivering peptide agonists with an attached (linker) small
molecule. This strategy allows for the selective delivery of a com-
plex molecule to particular target cells (Finan et al., 2012). In the
first usage of this strategy, researchers capitalized on the mono-
agonistic properties of GLP-1 and the sex steroid hormone, es-
trogen, to improvemetabolic parameters of obesity and T2DM. A
fully active GLP-1 agonist stably linked to estrogen consistently
proved to be more efficacious in lowering body weight than
either molecule alone. Additionally, these effects of the GLP-
1::estrogen conjugates were independent of adverse gyneco-
logical and oncogenic outcomes. This strategy appears to
uniquely combine potency with specificity; however, the molec-
ular mechanism of these beneficial effects remains to be eluci-
dated. Importantly, these co-agonist data suggest that the
maximally achievable and sustainable body-weight loss of
10%, observed with currently available pharmaceutics, may
not reflect an insurmountable physiological barrier (Day et al.,
2009). Hence, co-agonistic pharmacotherapy as well as varied
leptin sensitizers and new classes of chemical compounds
hold promise as an efficacious approach in the management of
obesity.
Finally, it must be noted that novel centrally acting molecules
regulating metabolism are regularly being discovered. Among
other examples, FGF21 was recently described as a potent
anti-obesity factor predominately affecting energy expenditure
(Bookout et al., 2013; Owen et al., 2014; Sarruf et al., 2010)
and, in humans, exhibiting a marked lipid-lowering effect (Gaich
et al., 2013). Based on genetic studies in rodents, the anti-
obesity actions of FGF21 have been attributed to its direct action
on the nervous system (Bookout et al., 2013; Owen et al., 2014;
Sarruf et al., 2010). However, concurrent data indicate that the
adipose tissue, rather than the nervous system, is required for
FGF21 anti-obesity actions (Adams and Kharitonenkov, 2012).
The regulation of glucose metabolism by FGF21 has also been
attributed to direct actions on the liver (Adams and Kharitonen-
kov, 2012). Further work should paint a fuller picture of
FGF21’s activities, and overall, the field is hopeful that existing
and/or novel ligands currently under development will be effica-
cious in the treatment of obesity.
Device-Assisted Neuromodulatory Techniques
Device-assisted neuromodulation refers to delivery of an electri-
cal current to either a specific nerve or a particular brain region in
order to influence brain activity and autonomic outflow. Devices
include but are not limited to stimulators of the spinal cord, vagus
nerve, and sacral nerve; deep brain stimulators; and gastric elec-
tric stimulators. Although many of these devices have not been
approved by the FDA for the treatment of metabolic disorders,
accumulating evidence suggests that modulation of targeted
brain sites or peripheral nerve activity by device-assisted means
is a valuable tool in the treatment of many chronic diseases
(Famm et al., 2013).
The idea of being able to target a particular brain site is attrac-
tive, considering the unwanted effects of many pharmacological
compounds. Furthermore, peripheral nerves are increasingly
recognized to play a critical role in metabolic functions (Bartness
et al., 2014; Powley et al., 2005). The vagus nerve is amixed (sen-
sory and motor) nerve that innervates most of the thoracic and
the abdominal viscera, including the entire gastrointestinal tract,
pancreas, and liver (Berthoud and Neuhuber, 2000). It is well es-
tablished that vagal sensory neurons convey a wide variety of
signals originating from the gastrointestinal tract, including me-
chanical stretch, changing levels of nutrients, lipids, immune sig-
nals, and gut peptides (de Lartigue et al., 2011). Experimental
observations also indicate the reduced ability of vagal afferents
to respond to dietary and endogenous metabolic signals in ani-
mals fed on high-fat diets (Kentish et al., 2012). These observa-
tions strongly support the idea that the vagus nerve serves as a
critical link between the gut and the brain and that this link is
impaired in obesity. Based on the aforementioned literature link-
ing vagal afferents to post-prandial functions and the regulation
of feeding, stimulation of vagal afferents has been hypothesized
to be a promising anti-obesity approach and a potential alterna-
tive to bariatric surgery (Powley et al., 2005). Pre-clinical studies
in large animals and humans suggest that vagus nerve stimula-
tion (VNS) might show efficacy in reducing food craving and
weight gain (Pardo et al., 2007; Val-Laillet et al., 2010). A tech-
nique of vagal blocking has also been tested in pre-clinical
studies (VBLOC) and recently approved by the FDA as a
weight-loss treatment device in obese individuals. Briefly, this
technique targets the nerve pathway between the brain and
the stomach by stimulating the vagal trunks at high frequency,
thus interfering with normal gastric functions and leading to early
satiation (Camilleri et al., 2008). However, contradictory results
have been obtained as to the benefits of this novel weight-loss
approach in obese subjects, with a couple of studies suggesting
a significant weight loss and reduced food craving (Camilleri
et al., 2008; Shikora et al., 2013), and others finding no significant
benefits (Ikramuddin et al., 2014; Sarr et al., 2012).
Central neurostimulatory techniques may also be of interest
in the treatment of obesity. In particular, high-frequency deep
brain stimulation (hfDBS, Table 1) has been effective at treating
the symptoms associated with Parkinson’s disease and other
disabling neurological disorders by normalizing pathological pat-
terns of neuronal activity (Wichmann and Delong, 2006). This
technique involves the chronic implantation by stereotaxic sur-
gery of stimulation electrodes in a targeted brain site. Electric
current is delivered to electrodes connected to a pulse generator
similar to a pace maker. Stimulation of the hypothalamus in hu-
mans is feasible and has been recently used in morbidly obese
humans to target the LHA (Whiting et al., 2013). Stimulation of
the LHA succeeded in increasing resting metabolic rate, leading
to reduced binge-eating scores and/or body weight in all three
test subjects. Similar results were obtained in a rat model, sup-
porting the idea that this technique could be considered as an
option for the treatment of obesity (Soto-Montenegro et al.,
2014).
It should be noted that brain surgery is associated with
inherent risks of hemorrhage, infection, and post-surgical com-
plication. Less invasive strategies that target the activity of sub-
populations of neurons may pose fewer concerns. In particular,
transcranial direct current stimulation (tDCS) is emerging as apromising technique for non-invasive neuromodulation in a
variety of clinical conditions (Dayan et al., 2013). This approach
allows for the modification of neuronal excitability in regions
involved in specific behaviors by delivering a weak current
through the scalp (Dayan et al., 2013). Thus, tDCS is suited for
cortical targets, specifically lateral and dorsomedial sectors of
the prefrontal cortex that contribute to cognitive control. Impor-
tantly, this technique has shown promise for acutely reducing
food craving (Fregni et al., 2008; Montenegro et al., 2012) and
may be suitable for obese individuals (Boggio et al., 2009;
Truong et al., 2013). Although the field embraces these novel
methodologies, others are still needed in order to facilitate ther-
apeutic opportunities in the treatment of various neurological pa-
thologies, including those contributing to obesity.
Treating Diabetes by Targeting the Brain
Many of the currently available drugs to treat T2DM are periph-
erally acting compounds (Table 1). This includes molecules
acting on glucose co-transporters, incretin (gastrointestinal
hormone that stimulates a decrease in blood glucose levels)
degradation enzymes, nuclear receptor signaling, and bile acid
metabolism. The most widely prescribed anti-diabetic drug in
the world is Metformin (Glucophage, Glumetza, Glucophage
XR, or Fortamet), a suppressant of hepatic glucose production
with few severe side effects (Garber et al., 1997). Likely due to
their minimal effect on the brain, these peripherally acting agents
marginally affect appetite. Overall, the popularity of each of these
drugs in the medical community is largely determined by their
benefit-risk profile.
Importantly, Claude Bernard’s idea that mechanisms behind
diabetes may have an origin in the CNS has been largely vali-
dated by modern physiological approaches (Obici and Rossetti,
2003; Pocai et al., 2005; Seeley and Tscho¨p, 2006). Over the past
two decades, it has become apparent that many of the currently
available anti-diabetic drugs also act directly in the CNS (Table 1
and Figure 2). For instance, Liraglutide and Exenatide are known
to act both in the periphery and at the level of the brain (Mul et al.,
2013; Sisley et al., 2014). However, one recent study demon-
strates that the glucose-lowering effects of Liraglutide are inde-
pendent of GLP-1 receptor signaling in the brain (Sisley et al.,
2014). Instead, the GLP-1 anti-diabetic actions in the periphery
have been well studied, as the naturally occurring pancreatic-
derived peptide GLP-1 was initially described as an incretin-
like peptide that controls blood glucose (Drucker, 2001).
Central 5-HT2C receptor agonism is involved in glycemic con-
trol (Berglund et al., 2013; Nonogaki et al., 1998; Xu et al., 2010a),
actions that are independent of its effects on food intake and
bodyweight. In particular, deletion of the 5-HT2CR in inmice defi-
cient for the peptide leptin leads to synergistic impairment of
glucose balance, independent of additional obesity compared
to ob/ob mice (Wade et al., 2008). Furthermore, 5-HT2CR
signaling in the hypothalamus has also been linked to glucose
metabolism (Xu et al., 2010a). It is therefore conceivable that
the reported beneficial effect of Lorcaserin on T2DM (O’Neil
et al., 2012) may be linked to its central actions in neurons regu-
lating glycemia.
It is now clear that the anti-diabetic and anti-obesity actions of
Mc4 receptors are independent and mediated by distinct neuralCell 161, March 26, 2015 ª2015 Elsevier Inc. 139
substrates. For example, humans deficient forMc4 receptors are
hyperinsulinemic, more so than would be expected from their
degree of obesity alone (Farooqi and O’Rahilly, 2005). Recent
genetic studies in the mouse have elegantly demonstrated that
restoration of Mc4 receptors in brainstem cholinergic neurons
normalizes hyperinsulinemia in an Mc4 receptor-deficient
background (Myers and Olson, 2012). Conversely, the selective
deletion of Mc4 receptors in the cholinergic neurons alone is suf-
ficient to raise insulin levels (Sohn et al., 2013). However, the
deletion of Mc4 receptors in both sympathetic and parasympa-
thetic neurons is required in order to lead to hyperglycemia and
insulin resistance (Berglund et al., 2014). Hence, Mc4 receptor
agonism in the nervous system would appear as a promising
anti-diabetic approach if these beneficial effects can be isolated
from the aforementioned adverse side effects.
New experimental data indicate that targeting the brain is
highly relevant to the treatment of type I diabetes (T1D). Leptin
has recently been shown to normalize glucose levels in rodents
with T1D, an effect that might be dependent upon leptin receptor
signaling in Pomc neurons and the regulation of the hypothalam-
ic-pituitary-adrenal (HPA) axis (Fujikawa et al., 2013; Perry et al.,
2014). Surprisingly, leptin appears sufficient to prevent death
and restore normoglycemia, even in the absence of insulin ther-
apy (Fujikawa et al., 2013). Leptin has also been shown to be
useful for the treatment of other metabolic disorders character-
ized by hypoleptinemia, which can be the result of congenital
or acquired lypodystrophies involving selective loss of fat and,
in some cases, severe insulin resistance, dyslipidaemia, hepatic
steatosis, and diabetes (Javor et al., 2005; Oral et al., 2002;
Petersen et al., 2002). The FDA has approved MYALEPT Metre-
leptin (trade name: MYALEPT), a synthetically derived analog of
leptin, for the treatment of lipodystrophy-related metabolic dis-
orders. Leptin monotherapy in mice (Gavrilova et al., 2000; Shi-
momura et al., 1999) and in patients suffering from generalized
lipodystrophy results in improvements of several metabolic pa-
rameters, including lowering of triglyceride and glucose levels
as well as hepatic steatosis (Javor et al., 2005; Oral et al.,
2002; Petersen et al., 2002). Moreover, after just a few months
of leptin therapy, many lipodystrophic patients no longer require
pharmacotherapy (e.g., insulin) to regulate glucose levels.
As previously outlined, amylin is an endogenous peptide dir-
ectly acting on the nervous system and able to potentiate leptin
sensitivity (Ravussin et al., 2009). An amylin analog (pramlintide)
is approved for T1D and T2DM in combination with insulin under
the trade name Symilin (Herrmann et al., 2014). Whereas the
mechanism of action of pramlintide on glucose regulation is
not well documented, the involvement of the brain in its anti-dia-
betic actions cannot be ruled out.
At first glance, given the efficacy and large choice of currently
available anti-diabetic drugs acting in the periphery, the neces-
sity for developing centrally acting anti-diabetic compounds is
not immediately clear. However, it is also evident that centrally
acting agents can effectively alleviate diabetes. This may
become useful when peripherally acting agents are not well
tolerated in certain T2DM patients and also in subjects with
poorly controlled T1D. Furthermore, centrally acting agents
commonly show a broader spectrum of actions on varied meta-
bolic functions. In particular, the ability of many central agents to140 Cell 161, March 26, 2015 ª2015 Elsevier Inc.simultaneously affect energy expenditure, appetite, cardiovas-
cular function, and glucose metabolism makes them particularly
relevant for the treatment of the metabolic syndrome. In sum-
mary, the brain should be (re)-considered as a prime target in
designing therapeutics for diabetes, especially in individuals
with multiple comorbidities.
Is the Brain Involved in the Metabolic Outcomes of
Bariatric Surgery?
A number of different approaches to bariatric surgery, also
known as gastric bypass, have been described (for review, see
Lutz and Bueter, 2014; Stefater et al., 2012). Roux-en-Y gastric
bypass is the most efficacious and frequently performed
weight-loss surgery (Buchwald, 2014; Lo Menzo et al., 2014;
Schauer et al., 2003). However, the use of sleeve gastrectomy
has been gaining in popularity in recent years since the approval
of laparoscopic sleeve gastrectomy in 2005. Patients eligible for
either sleeve gastrectomy or Roux-en-Y gastric bypass can
reasonably expect a near normalization of their body mass index
and reversal of most co-morbidities within 2 years. Despite their
remarkable efficacy, these surgeries remain costly procedures
associated with many complications. Perhaps weight-loss sur-
geries could be simplified and their complications avoided if
the biological mechanisms underlying their effects were under-
stood. Thus, many investigators acknowledge that identifying
the mechanisms underlying the beneficial effects of gastric
bypass is an important challenge. There is now ample evidence
that neither the mere physical restriction of the stomach nor
nutrient malabsorption is sufficient to explain weight loss and
glucose-metabolism improvement after bariatric surgery (Lutz
and Bueter, 2014; Stefater et al., 2012). At the physiological level,
a combination of modified parameters, including reduced appe-
tite, modified food preference, and augmented energy expendi-
ture, may collectively mediate weight loss after bariatric surgery.
At the cellular level, numerous non-exclusive factors have been
implicated in the benefits of bariatric surgery, including, but not
limited to, elevated levels of gut peptides and bile acids secre-
tion, enhanced intestinal growth, and changes in themicrobiome
composition (Lutz and Bueter, 2014). At the molecular level, far-
senoid-X receptor (FXR), a nuclear receptor for bile acids, has
been recently demonstrated to play a key role inmediating weigh
loss after Roux-en-Y gastric bypass (Ryan et al., 2014). Interest-
ingly, a recent study further demonstrated that intestinal FXR ag-
onism is sufficient to attenuate diet-induced obesity and insulin
resistance in the mouse (Fang et al., 2015).
The role played by the brain in mediating the benefits of bariat-
ric surgery remains open to discussion. At the phenomenological
level, the absence of compensatory hunger after bariatric sur-
gery in the face of considerable weight loss suggests major ad-
aptations in hunger pathways and the neural circuits involved in
the regulation of body-weight set-point. Whereas the nature of
these changes remains unknown, numerous experimental and
clinical observations indicate that profound adaptations occur
in the gut-to-brain axis after bariatric surgery: (1) Gastric bypass
surgery significantly improves post-prandial functions (Borg
et al., 2006; Thirlby et al., 2006), suggesting a modified func-
tioning of the gut-brain axis. (2) Augmented c-Fos expression
in the brainstem in response to gavage administration of lipid
emulsion (trade name: Intralipid) further supports the view that
vagal sensory neurons may behave differently after sleeve
gastrectomy (Chambers et al., 2012). (3) Following Roux-en-Y
gastric bypass and sleeve gastrectomy, animals eat more
frequent meals of smaller size (Stefater et al., 2010; Zheng
et al., 2009); a similar phenomenon has been described in hu-
mans after Roux-en-Y gastric bypass (Laurenius et al., 2012).
(4) Roux-en-Y gastric bypass in rats reduces the excitability of
vagal efferents (Browning et al., 2013). Furthermore, Mc4 recep-
tor signaling in mouse vagal efferents is required for diabetes
reversal after Roux-en-Y gastric bypass (Zechner et al., 2013).
(5) Destroying sensory afferents using capsaicin largely prevents
the anti-diabetic actions of entero-gastro anastomosis in rats
(Troy et al., 2008). (6) Indirect evidence also suggests that the
activity of high-order brain sites may be modified after bariatric
surgery. For instance, altered food preference (Shin et al.,
2013; Wilson-Pe´rez et al., 2013) and increase in the risk of alco-
holism after gastric bypass in humans (Ostlund et al., 2013; Su-
zuki et al., 2012) strongly suggest modified reward functions.
Brain-imaging studies have also revealed altered dopamine
receptor 2 availability after Roux-en-Y gastric bypass (Steele
et al., 2010). (7) One study reported a reduced hypothalamic ac-
tivity in response to food cues after gastric banding (Bruce et al.,
2012). According to another study (Stefater et al., 2010), sleeve
gastrectomy in the rat does not impact the expression levels
of hypothalamic neuropeptides. Further research is needed to
determine to what extent the vagal and brain changes discussed
above may, at least in part, be causally implicated in the benefits
of bariatric surgery.
Looking ahead to Unconventional Brain Therapies in
Metabolism
In 1974, the stereotaxic destruction of the lateral hypothalamus
was attempted in obese humans. It had been firmly anticipated
that this procedure would lead to reduced appetite and weight
loss, based on the previously described anorectic phenotype af-
ter lateral hypothalamus lesions in the rat. Unfortunately, the
obese individuals enrolled in this trial did not respond to the pro-
cedure. Important ethical and technical constraints have limited
progress in this area, and to the best of our knowledge, similar
invasive neurosurgical interventions have not been attempted
since. Nonetheless, the concept of altering the integrity of select
brain circuits to cure obesity still garners support in the scientific
community, and at least two major technical avenues for thera-
peutic intervention are currently being explored.
One involves cell transplantation technologies. For instance,
the transplant of leptin-sensitive neurons into the hypothalamus
of leptin receptor-deficient mice resulted in a diminished obesity
phenotype (Czupryn et al., 2011). The other involves chemo-
and optogenetics in which experimenters selectively silence or
activate subtypes of neurons and their connections (Lichtman
et al., 2008; Deisseroth, 2012; Urban and Roth, 2015). Unfortu-
nately, there is no currently available experimental evidence to
suggest that sustained weight loss and/or T2DM reversal could
be achieved using this kind of approach, and it remains unclear
whether opto- and chemogenetic techniques in their current
iterations will be a viable therapeutic in the treatment of various
diseases in humans. However, the following observations offerclues that the application of these technologies to the human
brain may be feasible in the near future: (1) Virally mediated
gene delivery has been attempted on many occasions in the
non-human primate brain and at least once in the human brain.
(2) Clozapine-N-oxide, an exogenous ligand commonly used in
chemogenetic experiments, has been safely administered to hu-
mans. (3) The applicability of optogenetics to the non-human pri-
mate brain has been validated. Certainly, for both transplantation
and acute manipulation of selectively labeled neurons, ethical
and safety concerns will be an important consideration for clin-
ical application.
Conclusions
In order for currently available drug therapies and weight-loss
surgeries to be maximally effective in severely obese subjects,
a careful nutritional management and monitoring of dietary
habits is required. A major goal of current obesity research is
to identify pharmacological compounds that would mimic the
effect of bariatric surgery without the inherent complexity and
potential risks of the surgery. New drugs are continuously in
development, but to date, none have reached the efficacy and
spectrum of action of bariatric surgery. It is admittedly disap-
pointing that the tremendous progress in our understanding of
the neural pathways regulating metabolism has not yet resulted
in more clinically relevant progress and clearly not a cure for
obesity or T2DM. Nonetheless, the burgeoning field of combina-
torial pharmacology, device-assisted neuromodulation medi-
cine, and chemo- and optogenetics holds promise for more
effective and safer anti-obesity and anti-diabetic therapies. In
parallel, it is necessary to treat the symptoms and complications
of obesity with appropriate pharmacological and surgical
means. The field should also address the biology underlying hu-
man preferences for hypercaloric food, especially given the con-
stant or growing availability of these foods throughout the world.
Undoubtedly, an increased understanding of the brain pathways
regulating energy balance and glucose homeostasis will provide
insights that will facilitate the development of multi-faceted ap-
proaches to combat both obesity and diabetes.
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